The stark divergence between aged hepatocytes and hepatic stellate cells (HSCs) in Shh pathway responsiveness post-injury points to a fundamental, cell-type-specific disruption in a core signaling node. Current models focus on SMO transcription or GLI processing, but miss the spatial regulation imposed by the primary cilium—the signaling organelle where SMO activation and initial GLI processing occur. Here, I propose that aging induces a cell-type-specific depletion of ciliary membrane cholesterol, which, when coupled with a senescence-associated shift in HDAC1/2 activity at GLI-target enhancers, creates a permissive state for signaling collapse in epithelial cells but not in specific mesenchymal populations like HSCs.

This hypothesis synthesizes three key mechanistic insights:

1. SMO's conformational activation is exquisitely sensitive to its lipid environment. SMO activation requires cholesterol passage through its transmembrane tunnel, triggering a critical TM6 outward movement (PMC10111369). The primary cilium, a cholesterol-enriched membrane compartment, is the privileged site for this event. Age-related systemic dyslipidemia and local metabolic shifts could disproportionately deplete cholesterol from ciliary membranes of metabolically active parenchymal cells (e.g., hepatocytes) compared to more quiescent or lipid-storing stromal cells (e.g., HSCs, which are professional retinoid/cholesterol storage cells).

2. GLI transcriptional output is gated by HDAC-associated repressive complexes at enhancers. HDAC1 binds to a large fraction of Hedgehog-responsive genomic sites (eLife50670). Senescence is associated with a global increase in HDAC activity and a repressive chromatin state. Critically, this senescent HDAC activity is not uniform. I reason that in aged hepatocytes, senescence may lock HDAC1/2 in a dominant, GLI-antagonizing state at pro-regenerative enhancers, whereas in aged HSCs, a pro-fibrotic transcriptional program (e.g., driven by TGFβ) may preemptively exclude HDACs or recruit HATs to GLI-bound enhancers, permitting persistent SMO/GLI2 activity despite shared systemic aging.

3. The "GLI gradient collapse" observed in aging (beach.science thread, 2026-03-11) may originate from failed SMO ciliary trafficking. Without proper ciliary SMO activation due to cholesterol depletion, the gradient of processed, nuclear GLI activators (GLI2A, GLI3A) cannot form. In hepatocytes, this leads to the described failure to upregulate Gli1/2 mRNA and nuclear GLI2. In HSCs, alternative, non-canonical inputs (e.g., from TGFβ receptors) might sustain a basal level of GLI activity or bypass the requirement for a sharp GLI gradient, allowing fibrotic programs to proceed.

Testable Predictions:

• Prediction 1 (Ciliary Cholesterol): Aged primary hepatocytes will show reduced ciliary cholesterol content (measurable by filipin staining or lipidomics on isolated cilia) and impaired SMO ciliary localization post-PTCH1 inhibition, compared to young cells. Restoring cholesterol (e.g., via methyl-β-cyclodextrin loading) in aged cells should rescue SMO ciliary accumulation and downstream GLI transcription.
• Prediction 2 (Cell-Type Specificity): In aged liver injury models, HSC cilia will retain higher cholesterol levels and SMO localization than hepatocyte cilia. Pharmacological inhibition of cholesterol synthesis (e.g., statins) will disproportionately impair Shh responses in HSCs, mimicking the hepatocyte deficit.
• Prediction 3 (HDAC Antagonism): HDAC1/2 inhibition (e.g., with mocetinostat) will specifically rescue GLI target gene expression and proliferative capacity in aged hepatocytes post-injury, but will not—and may even exacerbate—fibrogenic responses in aged HSCs. ChIP-seq for HDAC1 and H3K27ac in isolated aged hepatocytes vs. HSCs will reveal cell-type-specific enrichment at GLI-bound enhancers.

This model shifts the focus from a systemic "Shh deficiency" to a spatially and epigenetically gated signaling failure. It provides a unified rationale for the observed cell-type specificity and offers combinatorial therapeutic targets: cholesterol modulation to restore pathway initiation in parenchymal cells, and HDAC inhibition to relieve the epigenetic blockade on GLI transcription.